https://doi.org/10.4081/itjm.2025.1870
First evidence of immunomodulation of the renin-angiotensin system through substance P/neurokinin 1 receptor: a case and control study in hypertension and cardiac patients
Published: 6 February 2025
Abstract Views: 787
PDF: 325
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Gaining knowledge about the differences in substance P (SP) and neurokinin 1 receptor (NK1R) levels between cardiac and hypertensive patients may help clarify how these neuropeptides could be involved in the pathophysiology of cardiovascular disorders. This study aimed to investigate the levels of SP and NK1R in individuals diagnosed with hypertension and cardiac conditions. Participants were chosen from a pool of hypertensive (n=30) and cardiac patients (n=35) in addition to a control group (n=12). Each participant was asked for their informed permission before any demographic data, medical history, and pertinent clinical data were gathered. Serum samples were obtained, and the levels of SP and NK1R were measured using the enzyme-linked immunosorbent assay. When compared to the control group, the levels of SP and NK1R in hypertension patients were considerably higher. The findings point to a possible link between SP/NK1R and hypertension. There was a noticeably greater percentage of men (68.6%) among cardiac patients. The levels of SP and NK1R in cardiac patients and the control group did not vary significantly. Among those with hypertension and cardiac diseases, smoking, family history, and a diet heavy in salt were the most common risk factors. The study discovered substantial variations in SP and NK1R levels between hypertensive patients and a control group, suggesting a link between these neuropeptides and hypertension. In the case of cardiac patients, however, no significant variations in SP and NK1R levels were identified as compared to the control group.
Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol 2020;16:223-37.
DOI: https://doi.org/10.1038/s41581-019-0244-2
World Health Organization. Cardiovascular diseases. Available from: https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1. Accessed on: 5/12/2023.
Tocci G, Sciarretta S, Volpe M. Development of heart failure in recent hypertension trials. J Hyperten 2008;26:1477-86.
DOI: https://doi.org/10.1097/HJH.0b013e3282fe1d3d
Roth GA, Johnson C, Abajobir A, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol 2017;70:1-25.
DOI: https://doi.org/10.1016/j.jacc.2017.04.052
Honore P, Rogers SD, Schwei MJ, et al. Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience 2000;98:585-98.
DOI: https://doi.org/10.1016/S0306-4522(00)00110-X
Fröde-Saleh TS, Calixto JB, Medeiros YS. Analysis of the inflammatory response induced by substance P in the mouse pleural cavity. Peptides 1999;20:259-65.
DOI: https://doi.org/10.1016/S0196-9781(98)00170-3
Haines KA, Kolasinski SL, Cronstein BN, et al. Chemoattraction of neutrophils by substance P and transforming growth factor-β1 is inadequately explained by current models of lipid remodeling. J Immunol 1993;151:1491-9.
DOI: https://doi.org/10.4049/jimmunol.151.3.1491
Cuesta MC, Quintero L, Pons H, Suarez-Roca H. Substance P and calcitonin gene-related peptide increase IL-1β, IL-6 and TNFα secretion from human peripheral blood mononuclear cells. Neurochem Int 2002;40:301-6.
DOI: https://doi.org/10.1016/S0197-0186(01)00094-8
Church DJ, Arkinstall SJ, Vallotton MB, et al. Stimulation of atrial natriuretic peptide release by neurokinins in neonatal rat ventricular cardiomyocytes. Am J Physiol Heart Circ Physiol 1996;270:H935-44.
DOI: https://doi.org/10.1152/ajpheart.1996.270.3.H935
Ho WZ, Lai JP, Zhu XH, et al. Human monocytes and macrophages express substance P and neurokinin-1 receptor. J Immunol 1997;159:5654-60.
DOI: https://doi.org/10.4049/jimmunol.159.11.5654
Goode T, O’Connell J, Sternini C, et al. Substance P (neurokinin-1) receptor is a marker of human mucosal but not peripheral mononulear cells: molecular quantitation and localization. J Immunol 1998;161:2232-40.
DOI: https://doi.org/10.4049/jimmunol.161.5.2232
Cook GA, Elliott D, Metwali A, et al. Molecular evidence that granuloma T lymphocytes in murine schistosomiasis mansoni express an authentic substance P (NK-1) receptor. J Immunol 1994;152:1830-5.
DOI: https://doi.org/10.4049/jimmunol.152.4.1830
Robinson P, Garza A, Moore J, et al. Substance P is required for the pathogenesis of EMCV infection in mice. Int J Clin Exp Med 2009;2:7-86.
Blum M, Metwali A, Kim-Miller M, et al. The substance P receptor is necessary for a normal granulomatous response in murine Schistosomiasis mansoni. J Immunol 1999;162:6080-5.
DOI: https://doi.org/10.4049/jimmunol.162.10.6080
Robinson P, Martin Jr. P, Garza A, et al. Substance P receptor antagonism for treatment of cryptosporidiosis in immunosuppressed mice. J Parasitol 2008;94:1150-4.
DOI: https://doi.org/10.1645/GE-1458.1
D’Souza M, Garza MA, Xie M, et al. Substance P is associated with heart enlargement and apoptosis in murine dilated cardiomyopathy induced by Taenia crassiceps infection. J Parasitol 2007;93:1121-7.
DOI: https://doi.org/10.1645/GE-596R1.1
Vogt S, Grosse R, Schultz G, Offermanns S. Receptor-dependent RhoA activation in G12/G13-deficient cells: genetic evidence for an involvement of Gq/G11. J Biol Chem 2003;278:28743-9.
DOI: https://doi.org/10.1074/jbc.M304570200
Sagi SA, Seasholtz TM, Kobiashvili M, et al. Physical and functional interactions of Gαq with Rho and its exchange factors. J Biol Chem 2001;276:15445-52.
DOI: https://doi.org/10.1074/jbc.M008961200
Brown JH, del Re DP, Sussman MA. The Rac and Rho hall of fame: a decade of hypertrophic signaling hits. Circ Res 2006;98:730-42.
DOI: https://doi.org/10.1161/01.RES.0000216039.75913.9e
Sah VP, Hoshijima M, Chien KR, Brown JH. Rho is required for Gαq and α1-adrenergic receptor signaling in cardiomyocytes. Dissociation of Ras and Rho pathways. J Biol Chem 1996;271:31185-90.
DOI: https://doi.org/10.1074/jbc.271.49.31185
Hoshijima M, Sah VP, Wang Y, et al. The low molecular weight GTPase Rho regulates myofibril formation and organization in neonatal rat ventricular myocytes: involvement of Rho kinase. J Biol Chem 1998;273:7725-30.
DOI: https://doi.org/10.1074/jbc.273.13.7725
Yanazume T, Hasegawa K, Wada H, et al. Rho/ROCK pathway contributes to the activation of extracellular signal-regulated kinase/GATA-4 during myocardial cell hypertrophy. J Biol Chem 2002;277:8618-25.
DOI: https://doi.org/10.1074/jbc.M107924200
Maruyama Y, Nishida M, Sugimoto Y, et al. Galpha12/13 mediates alpha(1)-adrenergic receptor-induced cardiac hypertrophy. Circ Res 2002;91:961-9.
DOI: https://doi.org/10.1161/01.RES.0000043282.39776.7C
Thorburn J, Xu S, Thorburn A. MAP kinase- and Rho-dependent signals interact to regulate gene expression but not actin morphology in cardiac muscle cells. EMBO J 1997;16:1888-900.
DOI: https://doi.org/10.1093/emboj/16.8.1888
Hines WA, Thorburn A. Ras and Rho are required for Gαq-induced hypertrophic gene expression in neonatal rat cardiac myocytes. J Mol Cell Cardiol 1998;30:485-94.
DOI: https://doi.org/10.1006/jmcc.1997.0613
Kuwahara K, Saito Y, Nakagawa O, et al. The effects of the selective ROCK inhibitor, Y27632, on ET-1-induced hypertrophic response in neonatal rat cardiac myocytes—possible involvement of Rho/ROCK pathway in cardiac muscle cell hypertrophy. FEBS Lett 1999;452:314-8.
DOI: https://doi.org/10.1016/S0014-5793(99)00680-8
Aoki H, Izumo S, Sadoshima J. Angiotensin II activates RhoA in cardiac myocytes: a critical role of RhoA in angiotensin II-induced premyofibril formation. Circ Res 1998;82:666-76.
DOI: https://doi.org/10.1161/01.RES.82.6.666
Clerk A, Sugden PH. Small guanine nucleotide-binding proteins and myocardial hypertrophy. Circ Res 2000;86:1019-23.
DOI: https://doi.org/10.1161/01.RES.86.10.1019
Sah VP, Minamisawa S, Tam SP, et al. Cardiac-specific overexpression of RhoA results in sinus and atrioventricular nodal dysfunction and contractile failure. J Clin Invest 1999;103:1627-34.
DOI: https://doi.org/10.1172/JCI6842
Łazarczyk M, Matyja E,. Lipkowski A. Substance P and its receptors—a potential target for novel medicines in malignant brain tumour therapies (mini-review). Folia Neuropathol 2007;45:99-107.
Vink R, Gabrielian L, Thornton E. The role of substance P in secondary pathophysiology after traumatic brain injury. Front Neurol 2017;8:304.
DOI: https://doi.org/10.3389/fneur.2017.00304
Alhelal MA, Palaska I, Panagiotidou S, et al. Trigeminal nerve stimulation triggers oral mast cell activation and vascular permeability. Ann Allergy Asthma Immunol 2014;112:40-5.
DOI: https://doi.org/10.1016/j.anai.2013.10.011
Brown T, Gonzalez J, Monteleone C. Angiotensin-converting enzyme inhibitor-induced angioedema: a review of the literature. J Clin Hypertens 2017;19:1377-82.
DOI: https://doi.org/10.1111/jch.13097
Levick SP, Murray DB, Janicki JS, Brower GL. Sympathetic nervous system modulation of inflammation and remodeling in the hypertensive heart. Hypertension 2010;55:270-6.
DOI: https://doi.org/10.1161/HYPERTENSIONAHA.109.142042
Brattström A, Seidenbecher T. Central substance P increased blood pressure, heart rate and splanchnic nerve activity in anaesthetized rats without impairment of the baroreflex regulation. Neuropeptides 1992;23:81-6.
DOI: https://doi.org/10.1016/0143-4179(92)90082-8
Moyes AJ, Stanford SC, Hosford PS, et al. Raised arterial blood pressure in neurokinin‐1 receptor‐deficient mice (NK1R−/−): evidence for a neural rather than a vascular mechanism. Exp Physiol 2016;101:588-98.
DOI: https://doi.org/10.1113/EP085347
Melendez GC, Li J, Law BA, et al. Substance P induces adverse myocardial remodelling via a mechanism involving cardiac mast cells. Cardiovasc Res 2011;92:420-9.
DOI: https://doi.org/10.1093/cvr/cvr244
Chottova Dvorakova M, Mistrova E, Paddenberg R,et al. Substance P receptor in the rat heart and regulation of its expression in long-term diabetes. Front Physiol 2018;9:918.
DOI: https://doi.org/10.3389/fphys.2018.00918
How to Cite
M. Alanazi, I., Mehboob, R., Tariq, A., Hameed, S., Malik, U., Sarwar, N., Shahid, I., & Mehboob, K. (2025). First evidence of immunomodulation of the renin-angiotensin system through substance P/neurokinin 1 receptor: a case and control study in hypertension and cardiac patients. Italian Journal of Medicine, 19(1). https://doi.org/10.4081/itjm.2025.1870
Copyright (c) 2025 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.